-
Q&A and Panel Discussion
6:40
-
Clinical experience with approved targeted therapies_Elizabeth Waxman, BSN, MSN, ANP-BC
12:29
-
Strategies to optimize outcomes with targeted therapies in NSCLC_Blanca Ledezma, NP
15:46
-
Overview of actionable mutations in NSCLC_Marianne Davies DNP, ACNP, AOCNP, FAAN
8:02
-
Antibody-Drug Conjugates in Lung Cancer_Benjamin Levy, MD
50:57
-
Addressing Disparities in Cancer Care: Incorporating Precision Medicine for Minority Populations_Narjust Duma, MD_Nathaniel Evans III, MD
44:14
-
Corey J. Langer, MD; Abramson Cancer Center, University of Pennsylvania; 5Live; #ASCO2021
5:43
-
Andreas N. Saltos, MD; Moffitt Cancer Center; 5Live; #IASLC21
13:27
-
Narjust Duma, MD; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center; 5Live; #IASLC21
5:10
-
Benjamin Besse, MD, PhD; Gustave Roussy Cancer Campus; 5Live; #IASLC21
6:36
-
Suresh Ramalingam, MD, FACP, FASCO; Winship Cancer Institute of Emory University; 5Live; #IASLC21
9:26
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company